Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Early data readout indicates a successful LPS human challenge trial
China marked Saturday the beginning of “Chun Yun”, the 40-day period for Lunar New Year travel in China. This was pre-pandemic the largest annual migration of people worldwide.
Three sources confirmed to Reuters that China is currently in negotiations with Pfizer Inc for a license that will allow Chinese drugmakers to produce and distribute a generic version of
Maiden US Laboratory FoodPrint® installation,
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
People in China’s major cities of Beijing, Shanghai, and Wuhan braved the cold to resume regular activity Monday. They were optimistic about the economic recovery of more people who have
Stock markets in the UK are either heading into a recession or already are. Many investors are concerned about what the future holds for them.
There was a slight problem for those looking to pick the winners for 2022, this time last year. At that point, hardly any of the black swans that we are
A brief rundown of Charles Archer’s Top 15 small-cap shares to consider for 2023.
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived